Diet and medication for ER+ metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new approach using a special diet combined with a medication to see if it can improve the effectiveness of hormone therapy for women with ER-positive, HER2-negative metastatic breast cancer. The trial will help determine if this diet can slow cancer growth and potentially delay the need for chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is ER positive (more than 10%) and HER2 negative.
- Your cancer must have grown or spread after prior treatment with an aromatase inhibitor or fulvestrant, with or without a CDK4/6 inhibitor (in the first or second line for metastatic disease).
- You must be postmenopausal, or if premenopausal, you must have ovarian suppression (via surgery or medication).
- You have measurable metastatic disease (cancer that has spread) and are in reasonably good health (performance status 0-2).
- You have adequate organ function, including blood counts, liver, and kidney function.
- You must be willing to undergo an optional tumor biopsy if needed for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This study tests whether a special anti-inflammatory diet can help reduce side effects in breast cancer survivors who are taking aromatase inhibitors after menopause. You would be randomly assigned to either follow the diet for 6 months or continue your usual diet, and your health will be monitored.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.